Financings in Brief: Daltex Medical Sciences
This article was originally published in The Gray Sheet
Executive SummaryDaltex Medical Sciences: Lowers the exercise price and extends the deadline to exercise its class A and B warrants. Effective Oct. 1, 1995, the Fairfield, New Jersey-based firm's class A warrants may be exercised for 25 [cents] a share (down from $3.25) until Dec. 31, 1995 (extended from Sept. 30, 1995). Effective April 1, 1996, class B warrants may be exercised for $3.25 per share (down from $5) until Dec. 31, 1996 (extended from March 31). In September 1994, Daltex extended the expiration dates of the class A and B warrants from Sept. 30, 1994 and March 31, 1995, respectively...
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.